CMR FigSearch
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Coburn, B.
Right arrow Articles by Finlay, B. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coburn, B.
Right arrow Articles by Finlay, B. B.

Next Article 

Clinical Microbiology Reviews, October 2007, p. 535-549, Vol. 20, No. 4
0893-8512/07/$08.00+0     doi:10.1128/CMR.00013-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Type III Secretion Systems and Disease

Bryan Coburn ,{dagger} Inna Sekirov,{dagger} and B. Brett Finlay*

Michael Smith Laboratories, University of British Columbia, Vancouver, British Columbia, Canada

Type III secretion systems (T3SSs) are complex bacterial structures that provide gram-negative pathogens with a unique virulence mechanism enabling them to inject bacterial effector proteins directly into the host cell cytoplasm, bypassing the extracellular milieu. Although the effector proteins vary among different T3SS pathogens, common pathogenic mechanisms emerge, including interference with the host cell cytoskeleton to promote attachment and invasion, interference with cellular trafficking processes, cytotoxicity and barrier dysfunction, and immune system subversion. The activity of the T3SSs correlates closely with infection progression and outcome, both in animal models and in human infection. Therefore, to facilitate patient care and improve outcomes, it is important to understand the T3SS-mediated virulence processes and to target T3SSs in therapeutic and prophylactic development efforts.


* Corresponding author. Mailing address: Michael Smith Laboratories, UBC, 301-2185 East Mall, University of British Columbia, Vancouver, British Columbia, Canada V6T 1Z4. Phone: (604) 822-2210. Fax: (604) 822-9830. E-mail: bfinlay{at}interchange.ubc.ca

{dagger} B.C. and I.S. contributed equally to this work.


Clinical Microbiology Reviews, October 2007, p. 535-549, Vol. 20, No. 4
0893-8512/07/$08.00+0     doi:10.1128/CMR.00013-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Vaccine Immunol.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.